ExoLytics
ExoLytics is an early-stage biotechnology startup focused on developing novel, innovative, and disruptive technologies to combat drug-resistant infectious diseases. The company harnesses endolysins, enzymes present in nature, to engineer safe, rapid, and effective antimicrobial therapies. It aims to develop and commercialize alternatives to antibiotics in response to the rise in antimicrobial drug resistance, which poses a challenge to global public health and presents market opportunities.
Industries
biotechnology
Nr. of Employees
small (1-50)
ExoLytics
Products
Precision Antimicrobial Therapies
Developing therapies using endolysins, natural enzymes, to combat drug-resistant infectious diseases.
Precision Antimicrobial Therapies
Developing therapies using endolysins, natural enzymes, to combat drug-resistant infectious diseases.
Services
R&D activities to design, engineer, and advance enzyme-based antimicrobial candidates targeting drug-resistant bacteria.
R&D activities to design, engineer, and advance enzyme-based antimicrobial candidates targeting drug-resistant bacteria.
Expertise Areas
- Endolysin-based therapeutic development
- Antimicrobial resistance solutions
- Protein/enzyme engineering for therapeutics
- Preclinical therapeutic development
Key Technologies
- Endolysins (phage-derived lytic enzymes)
- Enzyme engineering
- Enzyme-based antimicrobial therapeutics